Skip Navigation

European Heart Journal 1994 15(11):1566-1570;
Copyright © 1994 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by RAY, S. G.
Right arrow Articles by DARGIE, H. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by RAY, S. G.
Right arrow Articles by DARGIE, H. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1994 The European Society of Cardiology

Cardiorespiratory and symptomatic variables during maximal and submaximal exercise in men with stable effort angina: a comparison of atenolol and celiprolol

S. G. RAY, G. MCCANN, E. HENDERSON, N. MACFARLANE, J. CHRISTIE, J. NORRIE*, I. FORD*, S. GRANT{dagger} and H. J. DARGIE

Department of Cardiology Western Infirmary Glasgow Glasgow, U.K
*Robertson Centre for Biostatistics Glasgow, U.K
{dagger}Department of Sports Science, University of Glasgow Glasgow, U.K

Received 15 November 1993; revised 3 May 1994; .

Correspondence. Dr Simon Ray, Department of Interventional Cardiology, Vancouver General Hospital, 855 West 12th Avenue, Vancouver V5Z 1M9, British Columbia, Canada

Abstract

Celiprolol is a novel beta1 selective adrenoreceptor blocker with partial beta2 agonism and direct vasodilator activity. These ancillary properties may reduce symptomatic breathlessness and fatigue and modify respiration during exercise. To test this hypothesis 20 men with stable effort angina were enrolled in a double-blind crossover study to investigate the effects of atenolol 100 mg once daily (A) and celiprolol 400 mg once daily (C) on cardiorespiratory and symptomatic variables during maximal and submaximal exercise. Total exercise time on a modified Bruce protocol was similar on both treatments: C 12.5 min, A 13.1 min. During steady state submaximal exercise at 60.75% (mean 68%) of maximum work capacity, minute ventilation (C 33.81 min–1, A 33.51 min–1), oxygen uptake (C 14.6 ml.kg–1. min–1, A 151 ml. kg–1. min–1), respiratory exchange ratio (C0.89, A 0.87), ratio of VEI VCO2 (C33.6, A 33.4), ratio of VEIVO2 (C2.34, A 2.72), Borg perceived exertion score (C 11.2, A 10.9) and visual analogue scores for breathlessness (C 29.5, A 25.9) and muscle fatigue (C 28.9, A 26.0) were all similar on both treatments. At maximal exercise capacity on the modified Bruce protocol, minute ventilation (C 58.31 min–1, A 60.41 min–1), oxygen uptake (C 21.3 ml. kg–1. min–1, A 21.7ml. kg–1.min–1), respiratory exchange ratio (C 1.02, A.1.05), ratio VEIVCO2 (C 34.8, A 35.9), and ratio VEIVO2 (C2.80, A 2.83) were also similar on both drugs. Over a 10 day period anginal attacks (C 10.1 ± 10.4, A 5.4 ± 5.9) and sublingual GTN use (C 5.9 ± 10.3, A 4.4 ± 9.8) were both more frequent on celiprolol.

We conclude, that in comparison with atenolol, celiprolol did not modify respiration during either steady state submaximal or maximal exercise and did not alleviate symptomatic breathlessness and fatigue. However, symptomatic ischaemia was more frequent with celiprolol.

Key Words: Atenolol • celiprolol • exercise • angina • oxygen uptake • symptoms


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.